Targeted therapy in melanoma

Slides:

Advertisements

Similar presentations

Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC) Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,

Advertisements

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Stefano Caccavale, MD, Eleonora Ruocco, MD, PhD Clinics in Dermatology

Volume 3, Issue 2, Pages (March 2017)

Refractory cutaneous lichenoid sarcoidosis treated with tranilast

Ludwik Fleck ( ) and his contribution to dermatology

Bigger Foot: Kaposi's Sarcoma

Volume 4, Issue 6, Pages (July 2018)

Volume 2, Issue 6, Pages (November 2016)

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Leprosy mimicking basal cell carcinoma in a patient on fingolimod

Volume 4, Issue 2, Pages (March 2018)

Subcutaneous sarcoidosis: Is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? Iftikhar Ahmed, MD, Sujata R.

Volume 4, Issue 2, Pages (March 2018)

Pigmentation after using topical tacrolimus to treat lichen sclerosus: Possible role of stem cell factor Young Jin Kim, MD, Hee Young Kang, MD, PhD

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation Julie Charles, MD, PhD, Jean-Claude.

Volume 3, Issue 3, Pages (May 2017)

Melanoma in skin affected with keratoderma palmoplantaris hereditaria (Mal de Meleda): Treatment with excision and grafting Leonardo Sartore, MD, Matteo.

Rachel L. Kyllo, BS, Mary Kendall Parker, MD, Ilana Rosman, MD, Amy C

Cutaneous manifestations of obesity and themetabolic syndrome

A definitive case of metastatic folliculotropic melanoma

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Serkan Demirkan, MD, Özgür Gündüz, MD, Tuba Devrim, MD

Volume 1, Issue 6, Pages (November 2015)

Digital metastasis of tongue squamous cell carcinoma

Justin J. Leitenberger, BS, Cindy N. Berthelot, MD, Kristel D

Pyoderma gangrenosum in a patient with cutaneous T-cell lymphoma

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation Manali Phadke, Geoffrey T. Gibney, Carolyn J. Rich,

Scurvy in a patient on vemurafenib

Volume 2, Issue 6, Pages (November 2016)

Lupus erythematosus–like skin eruption after vemurafenib therapy

Volume 2, Issue 4, Pages (July 2016)

Chagas Disease: Coming to a Place Near You

Targeting T Cell Co-receptors for Cancer Therapy

Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome Alexander Kreuter, MD, Peter Altmeyer, MD

Keiran S.M. Smalley Journal of Investigative Dermatology

Volume 4, Issue 3, Pages (April 2018)

Intradermal injection of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus Andrew T. Goldstein, MD, Michelle King, MSc, Charles.

Linear IgA dermatosis after infliximab infusion for ulcerative colitis

Ken Shiraishi, MD, PhD, Koji Sayama, MD, PhD JAAD Case Reports

Volume 5, Issue 1, Pages (January 2019)

Prurigo nodularis after acupuncture

Volume 1, Issue 5, Pages (September 2015)

Volume 1, Issue 3, Pages (May 2015)

Autoimmune skin diseases and the metabolic syndrome

Charles Hilton Fagge ( ): an early skin physician in London

Volume 1, Issue 5, Pages (September 2015)

Reversibility of Blue-Gray Cutaneous Discoloration From Amiodarone

Verrucous epidermal nevus (VEN) successfully treated with indocyanine green (ICG) photodynamic therapy (PDT) Tae In Kim, MD, Ki Heon Jeong, MD, Min Kyung.

Volume 4, Issue 9, Pages (October 2018)

Tumor of follicular infundibulum–associated neoplasms

Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low- dose methotrexate Sarah Mattessich, BS, Katalin Ferenczi, MD, Jun.

Grace A. Hile, BS, Lori Lowe, MD, J. Michelle Kahlenberg, MD, PhD

Atopic dermatitis and the metabolic syndrome

Bridget E. McIlwee, DO, Ryan W. Hick, MD, Stephen E. Weis, DO

Sole-Searing Pain: Classic Kaposi's Sarcoma

Lauren R. Penzi, MD, Arturo Saavedra, MD, PhD, Maryanne M. Senna, MD

Olga Vornicova, MD, Gil Bar-Sela, MD JAAD Case Reports

Volume 5, Issue 4, Pages (April 2019)

Identification of novel targetable mutations in metastatic anorectal melanoma by next- generation sequencing Emily D. Cai, BA, Jinah Kim, MD, PhD JAAD.

Photosensitive Lichenoid Reaction to Torsemide—a Loop Diuretic

Emilie Doré Badje, MD, Trilok Tejasvi, MD, Alexandra Hristov, MD

Hemorrhagic bullous dermatosis caused by warfarin therapy

A subcutaneous nodule on the mid back

Transforming growth factor–β overexpression in cutaneous extramedullary hematopoiesis of a patient with myelodysplastic syndrome associated with myelofibrosis

Acanthosis nigricans in a patient with sarcoma of unknown origin

Grace A. Hile, BS, Lori Lowe, MD, J. Michelle Kahlenberg, MD, PhD

Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC) Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Volume 2, Issue 3, Pages (May 2016)

Presentation transcript:

Targeted therapy in melanoma Ragini R. Kudchadkar, MD, Keiran S.M. Smalley, PhD, L. Frank Glass, MD, James S. Trimble, MD, Vernon K. Sondak, MD Clinics in Dermatology Volume 31, Issue 2, Pages 200-208 (March 2013) DOI: 10.1016/j.clindermatol.2012.08.013 Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 1 Dramatic reduction in size of multiple subcutaneous nodules seen after 15 weeks of vemurafenib treatment in a patient with BRAF mutant melanoma refractory to standard therapy. (Reprinted with permission from Wagle N et al.52) Clinics in Dermatology 2013 31, 200-208DOI: (10.1016/j.clindermatol.2012.08.013) Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 2 Reduction in size of multiple dermal and subcutaneous nodules seen after 5 months of treatment with dabrafenib and trametinib in a patient with BRAF mutant melanoma refractory to six previous treatments including ipilimumab. The patient had not received prior vemurafenib. (Courtesy of Dr. Jeffrey Infante.) Clinics in Dermatology 2013 31, 200-208DOI: (10.1016/j.clindermatol.2012.08.013) Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 3 Cystic facial skin lesions in a patient treated with vemurafenib. Clinics in Dermatology 2013 31, 200-208DOI: (10.1016/j.clindermatol.2012.08.013) Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 4 Biopsy of one of the skin lesions from the patient shown in Figure 3 reveals dilated infundibula with follicular hyperplasia and hyperkeratosis (hematoxylin & eosin, original magnification ×50). Clinics in Dermatology 2013 31, 200-208DOI: (10.1016/j.clindermatol.2012.08.013) Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 5 Keratosis pilaris in a patient treated with vemurafenib. Clinics in Dermatology 2013 31, 200-208DOI: (10.1016/j.clindermatol.2012.08.013) Copyright © 2013 Elsevier Inc. Terms and Conditions